Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cem Gabay

Showing results (161-170 of 259) with videos related to

Pageof 26
Sort By:
Cytokine|May 3, 2008
The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33Gaby Palmer, Brian P Lipsky, Molly D Smithgall, et al.
Immunity, Inflammation and Disease|September 30, 2015
Atherosclerosis severity is not affected by a deficiency in IL-33/ST2 signalingPraxedis Martin, Gaby Palmer, Emiliana Rodriguez, et al.
Arthritis and Rheumatism|February 28, 2009
Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritisGaby Palmer, Dominique Talabot-Ayer, Céline Lamacchia, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|April 4, 2015
Intra-articular bioactivity of a p38 MAPK inhibitor and development of an extended-release systemJulie Pradal, Maria-Fernanda Zuluaga, Pierre Maudens, et al.
Arthritis and Rheumatism|December 31, 2005
The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: a population-based studyAxel Finckh, Julia F Simard, Jeffrey Duryea, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 26, 2016
The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial SpondyloarthritisMichael J Nissen, Adrian Ciurea, Jürg Bernhard, et al.
Cardiovascular Research|May 26, 2005
Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout miceFaten Merhi-Soussi, Brenda R Kwak, David Magne, et al.
Rheumatology (Oxford, England)|December 8, 2020
Detection of circulating highly expanded T-cell clones in at-risk individuals for rheumatoid arthritis before the clinical onset of the diseaseCéline Lamacchia, Zuleika Calderin Sollet, Delphine Courvoisier, et al.
Rheumatology International|February 11, 2020
Individual therapeutic DAS28-d<sub>crit</sub> responses differentiate between effectiveness of rheumatoid arthritis therapies and reflect patient-reported outcomes: retrospective analysis of DAS28 responses in comparative tocilizumab studiesMichaela Koehm, Matthew J McIntosh, Michael W Hofmann, et al.
Arthritis Research & Therapy|May 8, 2020
Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritisMatthias Jarlborg, Delphine S Courvoisier, Céline Lamacchia, et al.
Pageof 26

Showing results (161-170 of 259) with videos related to

Sort By:
Pageof 26
Cytokine|May 3, 2008
The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33Gaby Palmer, Brian P Lipsky, Molly D Smithgall, et al.
Immunity, Inflammation and Disease|September 30, 2015
Atherosclerosis severity is not affected by a deficiency in IL-33/ST2 signalingPraxedis Martin, Gaby Palmer, Emiliana Rodriguez, et al.
Arthritis and Rheumatism|February 28, 2009
Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritisGaby Palmer, Dominique Talabot-Ayer, Céline Lamacchia, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|April 4, 2015
Intra-articular bioactivity of a p38 MAPK inhibitor and development of an extended-release systemJulie Pradal, Maria-Fernanda Zuluaga, Pierre Maudens, et al.
Arthritis and Rheumatism|December 31, 2005
The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: a population-based studyAxel Finckh, Julia F Simard, Jeffrey Duryea, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 26, 2016
The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial SpondyloarthritisMichael J Nissen, Adrian Ciurea, Jürg Bernhard, et al.
Cardiovascular Research|May 26, 2005
Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout miceFaten Merhi-Soussi, Brenda R Kwak, David Magne, et al.
Rheumatology (Oxford, England)|December 8, 2020
Detection of circulating highly expanded T-cell clones in at-risk individuals for rheumatoid arthritis before the clinical onset of the diseaseCéline Lamacchia, Zuleika Calderin Sollet, Delphine Courvoisier, et al.
Rheumatology International|February 11, 2020
Individual therapeutic DAS28-d<sub>crit</sub> responses differentiate between effectiveness of rheumatoid arthritis therapies and reflect patient-reported outcomes: retrospective analysis of DAS28 responses in comparative tocilizumab studiesMichaela Koehm, Matthew J McIntosh, Michael W Hofmann, et al.
Arthritis Research & Therapy|May 8, 2020
Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritisMatthias Jarlborg, Delphine S Courvoisier, Céline Lamacchia, et al.
Pageof 26